Indeed, the activation of the PI3K-Akt-mTOR pathway induced by PTEN loss and anti-AR treatments may promote prostate cancer cells proliferation and survival in androgen-reduced conditions. The gene discussed is AKT1; the disease is prostate carcinoma.